Medicus Pharma has received Investigational New Drug (IND) authorization from the UAE Department of Health to start its Phase 2a PRECISION-E2 clinical trial. The study will evaluate Teverelix in about 84 women with moderate-to-severe symptomatic endometriosis, testing different doses and administration routes against placebo. This trial aims to combine genomic data with pharmacology to develop a precision medicine approach for endometriosis, potentially improving treatment personalization. The results will guide future dose selection, administration methods, and biomarker-driven therapies for estrogen-dependent diseases in women.
Arval, a major player in long-term vehicle leasing and mobility solutions, has finalized its acquisition of Athlon, formerly part of Mercedes-Benz Group. This deal creates a combined fleet of 2.3 million vehicles, making Arval and Athlon the co-leade...
Arval, a BNP Paribas subsidiary specializing in long-term vehicle leasing, has finalized its acquisition of Athlon, formerly part of Mercedes-Benz Group. This deal expands Arval's fleet to 2.3 million vehicles, making it a European co-leader in the s...
SCOR, a leading global reinsurer, announced that as of July 31, 2026, it has 179,400,399 shares composing its capital, with an equal number of theoretical voting rights. The company, known for its innovative risk management solutions, recorded 18.7 b...
SCOR, a global reinsurer, declared that as of July 31, 2026, it has a total of 179,400,399 shares and an equal number of voting rights. Each share has a nominal value of EUR 7.8769723. This disclosure is part of regulatory compliance under French Com...
Morgan Stanley lowered its price target for FMC Corporation to $12.00 from $15.50 due to challenges in the agricultural market, including cautious customer buying and unfavorable weather. FMC's Q2 revenue fell 17% to $867 million, but strong cost con...
